Michael P. Kane

2.8k total citations
103 papers, 1.8k citations indexed

About

Michael P. Kane is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Oncology. According to data from OpenAlex, Michael P. Kane has authored 103 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in Michael P. Kane's work include Diabetes Management and Research (21 papers), Diabetes Treatment and Management (19 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Michael P. Kane is often cited by papers focused on Diabetes Management and Research (21 papers), Diabetes Treatment and Management (19 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Michael P. Kane collaborates with scholars based in United States, Australia and United Kingdom. Michael P. Kane's co-authors include Robert S. Busch, Susan Goodin, Eric H. Rubin, Robert A. Hamilton, Ann W. Silk, Howard L. Kaufman, Hasan Rehman, Gary Bakst, Kiyoshi Tsuji and Jeffrey S. Stroup and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Diabetes.

In The Last Decade

Michael P. Kane

97 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael P. Kane United States 23 514 476 442 242 235 103 1.8k
Jian Chen China 25 335 0.7× 706 1.5× 283 0.6× 359 1.5× 159 0.7× 152 2.7k
Syed Sameer Aga India 22 472 0.9× 798 1.7× 248 0.6× 233 1.0× 176 0.7× 106 2.3k
Hong Sun China 27 200 0.4× 816 1.7× 442 1.0× 350 1.4× 207 0.9× 64 2.8k
Xianglan Zhang China 38 628 1.2× 1.0k 2.1× 357 0.8× 204 0.8× 254 1.1× 121 3.6k
Patrick J. Ward United States 21 226 0.4× 424 0.9× 304 0.7× 216 0.9× 213 0.9× 67 2.0k
Yuezhong Ren China 17 200 0.4× 611 1.3× 641 1.5× 271 1.1× 174 0.7× 38 2.4k
Bo Jin China 26 427 0.8× 710 1.5× 290 0.7× 450 1.9× 75 0.3× 97 2.1k
Sung‐Koo Kang South Korea 25 121 0.2× 523 1.1× 392 0.9× 250 1.0× 132 0.6× 60 1.6k
Fen Liu China 31 342 0.7× 1.3k 2.8× 364 0.8× 447 1.8× 168 0.7× 186 3.2k

Countries citing papers authored by Michael P. Kane

Since Specialization
Citations

This map shows the geographic impact of Michael P. Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Kane more than expected).

Fields of papers citing papers by Michael P. Kane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Kane. The network helps show where Michael P. Kane may publish in the future.

Co-authorship network of co-authors of Michael P. Kane

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Kane. A scholar is included among the top collaborators of Michael P. Kane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Kane. Michael P. Kane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kane, Michael P., et al.. (2024). Decarbonizing specialty chemical manufacturing: opportunities for electrochemists. RSC Sustainability. 3(1). 460–470.
2.
Silk, Ann W., Brendan D. Curti, Jennifer L. Bryan, et al.. (2023). A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. Frontiers in Oncology. 13. 1108341–1108341. 8 indexed citations
3.
4.
Solis‐Herrera, Carolina, Michael P. Kane, & Curtis Triplitt. (2023). Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical Diabetes. 42(1). 74–86. 12 indexed citations
5.
Kane, Michael P., et al.. (2020). Method for Simultaneous Determination of Free Concentration, Total Concentration, and Plasma Binding Capacity in Clinical Samples. Journal of Pharmaceutical Sciences. 110(3). 1401–1411. 11 indexed citations
6.
Silk, Ann W., Howard L. Kaufman, Brendan D. Curti, et al.. (2020). High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9. 1483–1483. 9 indexed citations
7.
Kane, Michael P., et al.. (2019). Pomalidomide desensitization for hypersensitivity: A case report. Journal of Oncology Pharmacy Practice. 26(5). 1244–1247. 1 indexed citations
8.
Weiss, Robert E., Amal Mansour, Claude E. Monken, et al.. (2019). Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Therapy. 27(6). 438–447. 6 indexed citations
9.
Riche, Daniel M., et al.. (2010). Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(9). 955–965. 6 indexed citations
10.
Fetterly, Gerald J., Thaddeus H. Grasela, Jeffrey W. Sherman, et al.. (2008). Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel. Clinical Cancer Research. 14(18). 5856–5863. 56 indexed citations
11.
Kane, Michael P., et al.. (2008). Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. Endocrine Practice. 14(3). 285–292. 65 indexed citations
12.
13.
Lindley, Celeste, Susan Goodin, Jeannine S. McCune, et al.. (2005). Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy. American Journal of Clinical Oncology. 28(3). 270–276. 30 indexed citations
14.
Stroup, Jeffrey S., Michael P. Kane, Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2004). The Utility of Insulin Glargine in the Treatment of Diabetes Mellitus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(6). 736–742. 4 indexed citations
15.
Kane, Michael P., Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2004). Substitution of Pioglitazone for Troglitazone in Patients with Type 2 Diabetes. Endocrine Practice. 10(1). 18–23. 3 indexed citations
16.
Stroup, Jeffrey S., Michael P. Kane, Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2003). The Diabetes Home Visitation Program. American Journal of Pharmaceutical Education. 67(3). 91–91. 1 indexed citations
17.
Kane, Michael P.. (2002). Diabetes unmasked by electric shock. Archives of Disease in Childhood. 86(3). 210–210. 2 indexed citations
18.
Kane, Michael P., et al.. (1999). Unlimited Opportunities for Environmental Interventions with Inner-City Asthmatics. Journal of Asthma. 36(4). 371–379. 26 indexed citations
19.
Zayas, Luis E., Carlos Roberto Jaén, & Michael P. Kane. (1999). Exploring Lay Definitions of Asthma and Interpersonal Barriers to Care in a Predominantly Puerto Rican, Inner-City Community. Journal of Asthma. 36(6). 527–537. 25 indexed citations
20.
Levin, Gary M., et al.. (1996). Preclinical Exposure in a Baccalaureate Program in Pharmacy. American Journal of Pharmaceutical Education. 60(2). 179–182. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jian Chen Breakdown of academic impact, for papers by Syed Sameer Aga Breakdown of academic impact, for papers by Hong Sun Breakdown of academic impact, for papers by Xianglan Zhang Breakdown of academic impact, for papers by Patrick J. Ward Breakdown of academic impact, for papers by Yuezhong Ren Breakdown of academic impact, for papers by Bo Jin Breakdown of academic impact, for papers by Sung‐Koo Kang Breakdown of academic impact, for papers by Fen Liu
Rankless by CCL
2026